ACE inhibitor

New Study Shows a Coordinated Care Approach Significantly Improves Quality of Care for Patients with Type 2 Diabetes and Heart Disease

Retrieved on: 
Monday, June 26, 2023
Myocardial infarction, Enzyme inhibitor, Diabetes, Education, Hospital, Feedback, Importance, Stroke, Duke University School of Medicine, Type 2 diabetes, Prescription, Woman, Cardiology, SGLT2, Associate, Patient, American Diabetes Association, ACE inhibitor, ASCVD, Moyamoya disease, Health, MPH, ADA, T2D, Asterixis, Pharmaceutical industry, Nursing, MD, Medicine

SAN DIEGO, June 26, 2023  /PRNewswire/ -- Today, findings from the COORDINATE-Diabetes trial demonstrated that multi-disciplinary care between cardiologists, diabetes specialists and other team members can significantly increase the prescriptions of evidence-based therapies to help treat patients with both type 2 diabetes (T2D) and atherosclerotic cardiovascular disease (ASCVD), commonly known as heart disease. The trial was presented as a late-breaking symposium today at the 83rd Scientific Sessions of the American Diabetes Association® (ADA) in San Diego, CA.

Key Points: 
  • The trial was presented as a late-breaking symposium today at the 83rd Scientific Sessions of the American Diabetes Association® (ADA) in San Diego, CA.
  • In the United States alone, up to two-thirds of patients with T2D develop ASCVD in their lifetime.
  • While ASCVD is associated with worse health outcomes in patients with diabetes compared to the general population, evidence-based therapies to reduce heart disease risk in adults with T2D are underused in clinical practice.
  • Findings show that coordinated care intervention can significantly improve the quality of care that high risk patients receive.

CinCor Pharma Announces Late-Breaking Presentation of Phase 2 BrigHtn Data for Baxdrostat in Treatment-Resistant Hypertension at the Upcoming 2022 American Heart Association Scientific Sessions

Retrieved on: 
Wednesday, September 28, 2022
Adult, ACE inhibitor, Safety, Cardiology, Time, Hypertension, American College, COVID-19, Blood pressure, Risk, Aldosterone, Randomness, Plasma protein binding, Efficacy, Population, American Heart Association, Kidney disease, Achievement, Stroke, U.S. Securities and Exchange Commission, Degenerative disease, ARBS, Annual report, CINC, AHA, NASDAQ, Security (finance), GLOBE, SEC, American College of Cardiology, Primary aldosteronism, C1-inhibitor, Death, Pharmaceutical industry, Patient, Collection

Baxdrostat is a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase.

Key Points: 
  • Baxdrostat is a highly selective, once daily, oral small molecule inhibitor of aldosterone synthase.
  • Results From a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Baxdrostat in Patients with Treatment-Resistant Hypertension
    Please visit the AHA Scientific Sessions Late-Breaking Science for the most current programming.
  • CinCor, founded in 2018, is a clinical-stage biopharmaceutical company with a mission to bring innovation to the pharmaceutical treatment of cardio-renal diseases.
  • Though often asymptomatic, hypertension significantly increases the risk of heart disease, stroke and kidney disease, amongst other diseases.

AirBoss Announces 2nd Quarter Results and Continued Strength in Its Opportunity Pipeline

Retrieved on: 
Thursday, August 4, 2022
SUV, International Financial Reporting Standards, Natural rubber, OEM, NIOSH, Technology, Growth, Investment, TSX, Office of Inspector General, U.S. Department of Health and Human Services, Traction, Board, Original equipment manufacturer, Research, Workforce, Adjustment, ACE inhibitor, Income, Health, Public expenditure, Powered air-purifying respirator, EBITDA, Solution, Plastech Engineered Products, COVID-19, Company, U.S. Department of Defense Strategy for Operating in Cyberspace, Mission statement, PAPR, International, Acquisition, Depreciation, TTM, IFRS, AEP, BOS, Color, PPE, Engineering, ADG, Rubber industry in Malaysia, HHS, OTCQX, Renewable energy, Medical device, Fine chemical, Retail, Risk management, AirBoss of America

Gross profit as a percentage of net sales decreased to 18.2% for 2022 year-to-date compared with 26.2% for 2021 year-to-date.

Key Points: 
  • Gross profit as a percentage of net sales decreased to 18.2% for 2022 year-to-date compared with 26.2% for 2021 year-to-date.
  • In both cases, the decreases were primarily the result of delivery of PAPRs and nitrile gloves to HHS in 2021.
  • Gross profit at AirBoss Defense Group decreased by 61.2% to $9,754 for the quarter and by 18.7% to $37,425 year-to-date, from the comparable periods in 2021.
  • Despite these evolving global challenges, AirBoss continues to focus on opportunities in AirBoss Defense Groups (ADG) opportunity pipeline, with strong traction for the quarter in at AirBoss Rubber Solutions (ARS) and continued diligent work to address the related impacts to AirBoss Engineered Products (AEP).

Aldeyra Therapeutics Announces Positive Top-Line Data from Phase 2 Dry Eye Chamber Clinical Trial of Reproxalap, an Investigational New Drug, Compared to Xiidra®

Retrieved on: 
Tuesday, January 11, 2022
Research, Clinical Trials, Biotechnology, General Health, Pharmaceutical, Health, Optical, Science, Oncology, Other Science, Securities Exchange Act of 1934, Eye, LinkedIn, Financial condition report, Private Securities Litigation Reform Act, SEC, Patient, Tears, Temperature, U.S. Securities and Exchange Commission, Therapy, Compte rendu, Duane syndrome, Prevalence, PMID, Risk, Ophthalmology, Clinical trial, COVID-19, Inflammation, Safety, Humidity, Disease, ACE inhibitor, Retinitis pigmentosa, Nasdaq, Marketing, Topical medication, Allergic conjunctivitis, Dry eye syndrome, Multimedia, Failure, Lubrication, Annual report, Dry, Irritation, Growth, Pain, RASP, United, Biomarker, Result, Toxicity, Conversation, Medicine, Lipid peroxidation, Psoriasis, Quality of life, Analysis, Stephanie White de Goede, Asthma, Twitter, Security (finance), Physician, Pharmaceutical industry, Facebook, Lifitegrast

The double-masked, crossover, single-center, Phase 2 clinical trial in 56 dry eye disease patients evaluated the activity of reproxalap compared to Xiidra for two endpoints: ocular discomfort symptom score and ocular itching symptom score.

Key Points: 
  • The double-masked, crossover, single-center, Phase 2 clinical trial in 56 dry eye disease patients evaluated the activity of reproxalap compared to Xiidra for two endpoints: ocular discomfort symptom score and ocular itching symptom score.
  • Symptoms were assessed approximately 15 minutes prior to chamber entry, and every 5 minutes beginning 5 minutes after chamber entry.
  • Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis.
  • Expression of Lipid Peroxidation Markers in the Tear Film and Ocular Surface of Patients with Non-Sjogren Syndrome: Potential Biomarkers for Dry Eye Disease.

BERG's Study Provides Biological Insights Into The Increased Incidence Of COVID-19 In The African American Population

Retrieved on: 
Wednesday, September 9, 2020
ACE inhibitor, Angiotensin-converting enzyme, Coronavirus disease, Medical specialties, Branches of biology, Organ systems, Angiotensin II receptor blocker, Antihypertensive drug

The study, published today in the Journal of Racial and Ethnic Health Disparities, highlights the increased frequency of an ACE deletion polymorphism in the African American population.

Key Points: 
  • The study, published today in the Journal of Racial and Ethnic Health Disparities, highlights the increased frequency of an ACE deletion polymorphism in the African American population.
  • This genetic aberration has a known association with risk of greater susceptibility to lung and kidney dysfunction, both underlying risk factors for COVID-19 infection, outcomes and increased fatality.
  • Results indicate a strong rationale for the use of ACE inhibitors (ACE-I) and ARBs (AT1 receptor blockers) as treatment intervention to mitigate serious complications in COVID-19 patients.
  • The significant genetic, scientific and clinical data provides a compelling argument for the use of ACE-I and ARBs in the clinical management of patients with COVID-19 infections to improve outcomes.

Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF

Retrieved on: 
Sunday, November 17, 2019
Heart diseases, RTT, Medical specialties, Cardiovascular diseases, Cardiovascular system, Cardiomyopathy, Heart failure with preserved ejection fraction, Complement deficiency, Angioedema, ACE inhibitor, Heart failure

"Understanding the correlation between time since hospitalization and treatment benefit may help inform optimization of care for patients with heart failure."

Key Points: 
  • "Understanding the correlation between time since hospitalization and treatment benefit may help inform optimization of care for patients with heart failure."
  • "These new data, suggesting potential benefit of Entresto beyond HFrEF, represent our ongoing work to develop treatments for patients, including for HFpEF, a complex condition with high unmet patient need."
  • Patients are not to take Entresto for at least 36 hours before or after they take an ACE inhibitor medicine.
  • Patients are not to take Entresto again if they have had angioedema while taking Entresto.

First patient treated in DIAMOND study to evaluate if Veltassa® (patiromer) improves outcomes by enabling long-term use of essential RAASi therapy

Retrieved on: 
Tuesday, May 21, 2019
Health, Biotechnology, Clinical trials, Pharmaceutical, Branches of biology, Medical specialties, Endocrine system, Peptide hormones, Endocrinology, RTT, Renal physiology, Renin, Chronic kidney disease, Aldosterone, Angiotensin, ACE inhibitor

View the full release here: https://www.businesswire.com/news/home/20190520005695/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20190520005695/en/
    Vifor Pharma today announced that treatment of the first patient in their global phase-IIIb DIAMOND study has begun.
  • The study will evaluate the potential of Veltassa to improve outcomes by enabling heart failure (HF) patients, with or without chronic kidney disease (CKD), to be treated with renin-angiotensin-aldosterone system inhibitors (RAASi) therapy in accordance with HF treatment guidelines1,2.
  • The DIAMOND study is designed to further support the use of Veltassa to effectively control high blood potassium levels, thereby enabling optimal RAASi therapy in HF patients.
  • RAASi therapy has been shown to improve cardiovascular and renal outcomes and is proven to prolong survival and reduce hospitalisation.

Novartis late-breaking data further support initiation of Entresto in hospital and as a first-choice systolic heart failure therapy in stabilized patients

Retrieved on: 
Saturday, March 16, 2019
Medicine, Branches of biology, Health, Heart diseases, Organ failure, Aging-associated diseases, RTT, Heart failure, Herbalism, ACE inhibitor, Medication, Acute decompensated heart failure

"Data from this 4-week extension of PIONEER-HF clearly support Entresto as a first-choice treatment upon systolic heart failure diagnosis or worsening of symptoms and underscore the importance of initiating Entresto in the hospital."

Key Points: 
  • "Data from this 4-week extension of PIONEER-HF clearly support Entresto as a first-choice treatment upon systolic heart failure diagnosis or worsening of symptoms and underscore the importance of initiating Entresto in the hospital."
  • Patients should talk to their doctor about other ways to treat heart failure if they plan to become pregnant.
  • Patients are not to take Entresto for at least 36 hours before or after they take an ACE inhibitor medicine.
  • Patients should tell their doctor about all the medicines they take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Global Hyperkalemia Drugs Market to 2023: Market will Grow at a CAGR of More than 20% with Ardelyx, AstraZeneca, Perrigo, Sanofi & Vifor Pharma Dominating

Retrieved on: 
Wednesday, January 9, 2019
RTT, Medicine, Kidney diseases, Anatomy, Organ failure, Nephrology, Potassium, Chronic kidney disease, Hyperkalemia, Chronic condition, ACE inhibitor, Kidney failure

The hyperkalemia drugs market will grow at a CAGR of more than 20% during the forecast period.

Key Points: 
  • The hyperkalemia drugs market will grow at a CAGR of more than 20% during the forecast period.
  • The growing cases of various chronic diseases such as chronic kidney diseases and cardiovascular-related disorders are driving the market growth.
  • Chronic kidney diseases increase the risk of patient developing hyperkalemia significantly, as the kidneys lose the ability to excrete potassium through urine.
  • The global hyperkalemia drugs market has witnessed a growth in recent years, primarily due to the increasing prevalence of the disease globally.